表观遗传药物联合抗PD-1重编程肿瘤微环境并恢复霍奇金淋巴瘤抗肿瘤疗效
在52例既往接受地西他滨联合抗PD-1(DP)治疗后复发/难治的经典型霍奇金淋巴瘤患者中,评估西达本胺、地西他滨和卡瑞利珠单抗三药方案(CDP)的疗效与安全性;CDP耐受良好,客观缓解率94%(95%CI 84-99),完全缓解率50%(95%CI 36-64),中位无进展生存29.4个月。
要点
- CDP方案在既往DP治疗失败的患者中客观缓解率94%,完全缓解率50%。
- 对DP原发耐药者CDP治疗后均出现治疗反应,但完全缓解率低于既往DP敏感者。
- 单细胞RNA测序揭示CD30+ HRS样细胞与IL21+CD4+ T细胞形成免疫抑制正反馈环。
核心结论
- 双表观遗传联合免疫治疗(CDP)在既往DP治疗后的经典型霍奇金淋巴瘤中显示出治疗有效性,并可克服免疫治疗耐药。
研究设计与样本
- 研究纳入52例既往接受地西他滨联合抗PD-1(DP)治疗后的经典型霍奇金淋巴瘤患者,评估西达本胺、地西他滨和卡瑞利珠单抗三药方案(CDP)的疗效与安全性,并进行治疗前后肿瘤活检样本的单细胞RNA测序。
- 试验注册号为NCT04233294。
主要发现
- CDP治疗耐受良好,客观缓解率为94%(95%CI 84-99),完全缓解率为50%(95%CI 36-64)。
- 所有对既往DP治疗无反应的患者在CDP治疗后均出现治疗反应,但其完全缓解率低于既往对DP有反应的患者。
- 中位无进展生存期为29.4个月。
- 治疗前CD30+ HRS样细胞与丰富的免疫抑制性IL21+CD4+ T辅助细胞相互作用,形成支持其存活的正反馈环;CD30- HRS样细胞群显示对抗PD-1免疫治疗有潜在耐药性。
- CDP治疗通过抑制STAT1/3信号促进多种肿瘤反应性CD8+ T细胞活化并抑制IL21+CD4+ T细胞增殖,从而减轻其免疫抑制作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DNA methyltransferase inhibitor decitabine plus anti-programmed cell death 1 (DP) therapy was effective in relapsed/refractory classic Hodgkin lymphoma (cHL). However, a subset of patients experienced primary resistance or relapse/progression after DP therapy. In this study, we evaluated the efficacy and safety of a triplet regimen consisting of the histone deacetylase inhibitor chidamide, decitabine, and anti-PD-1 camrelizumab (CDP) in 52 patients who previously received DP therapy. CDP treatment was well tolerated and resulted in an objective response rate of 94% (95% confidence interval [CI], 84-99), with 50% (95% CI, 36-64) of patients achieving complete response (CR). Notably, all patients who were recalcitrant to previous DP treatment exhibited therapeutic responses after CDP therapy, although their CR rate was lower than patients responsive to prior DP. Overall, the median progression-free survival was 29.4 months. Through single-cell RNA sequencing of pretreatment and on-treatment cHL tumor biopsy samples, we observed the heterogeneity of rare malignant Hodgkin Reed/Sternberg (HRS)-like cells. The classical CD30+ HRS-like cells interacted with abundant immunosuppressive IL21+CD4+ T helper cells, forming a positive feedback loop that supported their survival. While the CD30- HRS-like cell population showed potential resistance to anti-PD-1 immunotherapy. CDP treatment promoted the activation of diverse tumor-reactive CD8+ T cells and suppressed the proliferation of IL21+CD4+ T cells by inhibiting STAT1/3 signaling, thereby alleviating their immunosuppressive effects. These findings provide insights into the cHL microenvironment that contributes to anti-PD-1 resistance and highlight the therapeutic effectiveness of dual epi-immunotherapy in overcoming immunotherapy resistance. This trial was registered at www.clinicaltrials.gov as #NCT04233294.
引用
- Nie J, Wang C, Zheng L, et al. Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma. Blood. 2024. PMID: 39093981. doi:10.1182/blood.2024024487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。